Scholar Rock Holding Corporation stock is up 2.72% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 November’s closed higher than October. In the last 5 Unusual Options Trades, there were 5 CALLs.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|01 Nov 16:30||19 Apr, 2024||10.00||123|
|09 Nov 17:23||19 Jan, 2024||7.50||645|
|09 Nov 18:00||19 Jan, 2024||7.50||645|
|16 Nov 20:07||19 Jan, 2024||7.50||639|
|17 Nov 16:28||19 Jan, 2024||12.50||210|
Scholar Rock Holding Corporation focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin, and SRK-181, which is in Phase 1 clinical trials. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients.